AbbVie (ABBV) announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with ...

AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings experienced worse outcomes than observed in trials. Higher toxicity rates ...

Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company ...

Genmab (GMAB) A/S announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, plus ...